my personal edition > diabetes > news


  E-Mail this DGDispatch to a colleague

DGDispatch

Repaglinide Outperforms Nateglinide for Reducing Hemoglobin A1c and Fasting Plasma Glucose in Type 2 Diabetes: Presented at AACE

By Maury M. Breecher, PhD, MPH

SAN DIEGO, CA -- May 21, 2003 -- Repaglinide monotherapy was significantly more effective than nateglinide monotherapy for reducing hemoglobin A1c (HbA1c), and fasting plasma glucose (FPG) levels in patients with type 2 diabetes, according to a multicenter trial.

Results were presented on May 16^th here at the American Association of Clinical Endocrinologists 12^th Annual Meeting and Clinical Congress.

One hundred and forty patients took part in this 16-week, open-label, randomized, parallel-group study. Participants started with HbA1c values between 7% and 12% during a previous treatment of diet and exercise alone.

Both repaglinide and nateglinide had similar postprandial glycemic effects, but repaglinide monotherapy at a final dose of 6 mg/day, was clinically and statistically more effective than nateglinide monotherapy at a final dose of 360 mg/day, in reducing FPG and HbA1c values, according to lead study author Mohammed F. Saad, MD, Los Angeles Diabetes Center, Alhambra, Calif.

The 71 patients on repaglinide started with a baseline HbA1c of 8.9%, and had a mean change of –1.57 (P=0.002), compared with 69 patients on nateglinide who also had a baseline mean of 8.9, but had a mean change of –1.04 at the study end point. The repaglinide group had a –57 mg/dL mean change in FPG, and the nateglinide group had a –18 mg/dL change (P<0.001).

Minor hypoglycemic episodes occurred in 7% of repaglinide patients, but none of nateglinide patients. No episodes of major hypoglycemia were reported in either group.

The researchers concluded that repaglinide monotherapy was significantly more effective than nateglinide monotherapy in reducing HbA1c and FPG values in patients with type 2 diabetes, previously treated with diet and exercise.

This study was sponsored by Novo Nordisk Pharmaceuticals, Inc., Princeton, NJ.


[Study title: Repaglinide vs. Nateglinide Monotherapy: A Randomized, Multicenter, Open-Label Study. Abstract 44]

E-Mail this DGDispatch to a colleague

To print, use this version